Switch to:

Key Ratios

New Key Statistics Module, Z-Score and F-Score
Market Cap $M183,698Revenue $M51,584Net Margin (%)20.7Z-Score2.6
Enterprise Value $M187,826EPS $3.2Operating Margin %26.8F-Score6
P/E(ttm))18.2Cash Flow Per Share $3.5Pre-tax Margin (%)26.8Higher ROA y-yN
Price/Book2.410-y EBITDA Growth Rate %3.2Quick Ratio2.4Cash flow > EarningsY
Price/Sales3.85-y EBITDA Growth Rate %8.5Current Ratio2.7Lower Leverage y-yN
Price/Cash Flow7.2y-y EBITDA Growth Rate %2.3ROA % (ttm)6.0Higher Current Ratio y-yY
Dividend Yield %3.5Insider Buy (3m)0ROE % (ttm)13.4Less Shares Outstanding y-yY
Payout Ratio %63.0Shares Outstanding M6,379ROI % (ttm)21.6Gross Margin Increase y-yN

Gurus Latest Trades with PFE

Number of guru portfolios checked: 56. (List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)
TickerGuruDate Action
Impactup Price Range
(Average)*
Current Price Change from Average Comment Current Shares
PFERay Dalio 2013-09-30 Buy 0.01%$27.65 - $29.67
($28.69)
$ 29.222%New holding, 54608 sh.54,608
PFEJoel Greenblatt 2013-09-30 Add0.04%$27.65 - $29.67
($28.69)
$ 29.222%Add 259.55%65,050
PFEJean-Marie Eveillard 2013-09-30 Add0.44%$27.65 - $29.67
($28.69)
$ 29.222%Add 174.32%8,276,410
PFEVanguard Health Care Fund 2013-09-30 Reduce-0.27%$27.65 - $29.67
($28.69)
$ 29.222%Reduce -10.74%21,393,422
PFEJames Barrow 2013-06-30 Add0.12%$27.23 - $31.08
($29.12)
$ 29.220%Add 4.37%60,830,964
PFEDavid Dreman 2013-06-30 Reduce-0.02%$27.23 - $31.08
($29.12)
$ 29.220%Reduce -21.76%71,097
PFERay Dalio 2013-06-30 Sold Out -0.02%$27.23 - $31.08
($29.12)
$ 29.220%Sold Out0
PFEJoel Greenblatt 2013-06-30 Reduce-0.05%$27.23 - $31.08
($29.12)
$ 29.220%Reduce -66.69%18,092
PFEGeorge Soros 2013-06-30 Sold Out -0.06%$27.23 - $31.08
($29.12)
$ 29.220%Sold Out0
PFEJean-Marie Eveillard 2013-06-30 Reduce-0.34%$27.23 - $31.08
($29.12)
$ 29.220%Reduce -54.03%3,017,033
PFEVanguard Health Care Fund 2013-06-30 Reduce-0.87%$27.23 - $31.08
($29.12)
$ 29.220%Reduce -24.15%23,968,323
PFEMichael Price 2013-06-30 Reduce-0.91%$27.23 - $31.08
($29.12)
$ 29.220%Reduce -41.38%347,100
PFEYacktman Focused Fund 2013-06-30 Sold Out -2.21%$27.23 - $31.08
($29.12)
$ 29.220%Sold Out0
PFEDonald Yacktman 2013-06-30 Reduce-2.39%$27.23 - $31.08
($29.12)
$ 29.220%Reduce -99.74%41,700
PFEYacktman Fund 2013-06-30 Sold Out -2.65%$27.23 - $31.08
($29.12)
$ 29.220%Sold Out0
PFEJean-Marie Eveillard 2013-03-31 Add0.23%$25.079 - $28.86
($27.3)
$ 29.227%Add 57.8%6,562,712
PFERay Dalio 2013-03-31 Reduce-0.01%$25.079 - $28.86
($27.3)
$ 29.227%Reduce -26.27%57,808
PFERay Dalio 2012-12-31 Add0.01%$23.66 - $26.04
($25.01)
$ 29.2217%Add 73.45%78,400
PFEDavid Dreman 2012-12-31 Reduce-0.23%$23.66 - $26.04
($25.01)
$ 29.2217%Reduce -77.06%110,998
PFERonald Muhlenkamp 2012-12-31 Reduce-1.7%$23.66 - $26.04
($25.01)
$ 29.2217%Reduce -89.46%37,624
Premium Real Time Picks are included for Premium Members only!!
*The price and date might not be the actual time and price at which the transactions were made. In the case of institutional owners, the date is stated as the last day of their fiscal quarter. The prices are estimates if no accurate information available. Foreign holdings may not be included.

PFE is held by these Gurus:

Ticker Guru Name Portfolio Date* Current Shares % of Shares Outstanding % of Total Assets Managed Change from Last Holdings Holding History
PFE Ray Dalio 2014-06-30393,0080.010.09+250.56%
PFE Vanguard Health Care Fund 2014-06-3014,934,0220.231.2+105.23%
PFE Joel Greenblatt 2014-06-301,741,3140.030.65+71.59%
PFE David Dreman 2014-06-3013,61500.03+14.88%
PFE Charles Brandes 2014-06-306,075,4600.12.2+5.78%
PFE James Barrow 2014-06-3060,500,0580.952.4+1.01%
PFE Prem Watsa 2014-06-30235,00000.48
PFE Ruane Cunniff 2014-06-3010,98700-0.32%
PFE Ronald Muhlenkamp 2014-06-3041,01900.21-0.36%
PFE Mario Gabelli 2014-06-301,104,0700.020.17-5.28%
PFE John Keeley 2014-06-3089,83900.05-6.31%
PFE Dodge & Cox 2014-06-3048,902,0970.771.4-23.73%
PFE Michael Price 2014-06-30107,10000.39-69.14%
PFE Jean-Marie Eveillard 2014-06-302,303,7620.040.17-70.71%
PFE John Hussman 2014-06-30000Sold Out
Premium Most recent portfolio changes are included for Premium Members only!


PFE: Insider Buys/Sells

Click Here for All Insider Trades.
InsiderPosition Date Trades Shares Trade Price ($) Change (%) Details
OLSON LAURIE JExecutive Vice President 2014-06-12Sell36,275$29.531.29view
Germano Geno JGroup President 2014-06-02Sell30,000$29.680.77view
YOUNG JOHN DGroup President 2014-03-17Sell9,000$31.38-4.68view
PFIZER INC10% Owner 2014-03-12Buy272,727$11171.91view
CANGIALOSI LORETTA VSr. Vice President, Controller 2014-03-04Sell102,943$32.05-6.68view
Dolsten MikaelPresident R&D 2014-03-04Sell35,789$32.58-8.2view
SUSMAN SALLYExecutive Vice President 2014-03-04Sell67,585$32.59-8.22view
PFIZER INC10% Owner 2014-02-04Buy227,261$8273.88view
DAMELIO FRANK AExecutive Vice President 2014-01-13Sell131,810$30.82-2.95view
DAMELIO FRANK AExecutive Vice President 2014-01-13Sell28,190$30.86-3.08view

Press Releases about PFE :

Quarterly/Annual Reports about PFE:

    News about PFE:

    Articles On GuruFocus.com
    A Few Reasons Why AbbVie's Momentum Will Continue Sep 25 2014 
    The Dogs of the Dow Lost Some Steam In The August Heat, But Maintained Their Lead Sep 16 2014 
    The Dogs of the Dow Lost Some Steam In The August Heat, But Maintained Their Lead Sep 16 2014 
    I Am Sure This Pharma-Company Suits Your Portfolio Aug 28 2014 
    Higher Yielding Stocks With A Cheap EV/EBITDA Ratio And Low Debt Figures Aug 28 2014 
    Guru Stocks at 52-Week Lows: PFE, GSK, VOD, EC, MFG Aug 18 2014 
    A Strong Candidate for Investor´s Portfolios Aug 12 2014 
    Legendary Investor Irving Kahn's Top Five Stocks Aug 08 2014 
    Widely Held Guru Stocks Near 52-Week Lows Aug 05 2014 
    Guru Stocks at 52-Week Lows: PFE, GSK, VOD, EC, UBS Aug 04 2014 

    More From Our Partners
    GlycoMimetics Down Due to Delay in Rivipansel Study - Analyst Blog Sep 30 2014 - ZACKS

    More From Other Websites
    Viagra ads target women for 1st time Sep 30 2014
    [video] Viagra's New Ad Campaign to Target Women for First Time Sep 30 2014
    1:16 am Pfizer and Kyowa Hakko Kirin to collaborate on immuno-oncology combination study Sep 30 2014
    Pfizer And Kyowa Hakko Kirin To Collaborate On Immuno-Oncology Combination Study Sep 29 2014
    Pfizer And Kyowa Hakko Kirin To Collaborate On Immuno-Oncology Combination Study Sep 29 2014
    Business events scheduled for Tuesday Sep 29 2014
    Business events scheduled for Tuesday Sep 29 2014
    Pfizer Inc. Stock Fails To Break Out: Is It Headed Back Down? Sep 29 2014
    Why multinationals aren't adding U.S. jobs Sep 28 2014
    Pfizer drug effective in patients with rare lung cancer -study Sep 27 2014
    Pfizer’s Lung Cancer Drug Helps Patients With Gene Defect Sep 27 2014
    [video] Stock Pops & Drops: AGIO, MO, PFE & MU Sep 26 2014
    Pfizer Acquires InnoPharma, Injectables Business to Benefit Sep 26 2014
    Focusing Solely On Animal Health Sets Zoetis Apart Sep 26 2014
    GlycoMimetics Announces a Delay in the Initiation of the Phase 3 Trial With Rivipansel Sep 26 2014
    Pain Therapeutics Expands Pipeline With FENROCK(TM), an Abuse-Deterrent Pain Patch Sep 26 2014
    [video] Fast Money Final Trade: PFE, DOW, VRTX & the dollar Sep 25 2014
    Fast Money Final Trade: PFE, DOW, VRTX & the dollar Sep 25 2014
    Pfizer Completes Acquisition Of InnoPharma Sep 25 2014
    New FDA label bolsters safety case for Chantix Sep 24 2014

    Add Notes, Comments

    If you want to ask a question, or report a bug, please create a support ticket.

    User Comments

    SEENSCO
    ReplySEENSCO - 3 months ago
    PFE is trading at the low end of our short-term valuation range ($29-$36) and significantly below our Fair Value estimate of $42.41.
    Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
    GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
    Free 7-day Trial
    FEEDBACK